Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection
Background: All currently used therapeutic protocols and drugs for <i>Clostridioides difficile</i> infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + n...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/14/4/400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849712150477537280 |
|---|---|
| author | Jasna Rahimić Ervin Alibegović Lana Lekić Marijana Marković Boras Amina Džidić-Krivić Esma Karahmet Farhat Emina Karahmet Sher |
| author_facet | Jasna Rahimić Ervin Alibegović Lana Lekić Marijana Marković Boras Amina Džidić-Krivić Esma Karahmet Farhat Emina Karahmet Sher |
| author_sort | Jasna Rahimić |
| collection | DOAJ |
| description | Background: All currently used therapeutic protocols and drugs for <i>Clostridioides difficile</i> infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a therapeutic protocol for a medium–severe form of CDI. In addition, the effects of a modified therapeutic protocol with standard monotherapy on the number of stools and stool consistency in a medium–severe CDI will be compared. Materials and Methods: A prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group of patients was treated with vancomycin monotherapy. The other group was treated with the modified therapeutic protocol (vancomycin + nifuroxazide). Results: The modified therapy with vancomycin + nifuroxazide demonstrated enhanced pharmacological efficacy in the management of CDI compared to the standard vancomycin monotherapy. Patients treated with dual therapy reported a significantly lower number of stools in first, second and third control; first control (4.47 ± 2.20 compared to 5.70 ± 1.91 in vancomycin group (<i>p</i> = 0.024)), second control (2.37 ± 0.85 compared to 3.13 ± 0.90 in vancomycin group (<i>p</i> = 0.001)), and third control (1.53 ± 0.51 compared to 1.80 ± 0.61 in vancomycin group (<i>p</i> = 0.035)). Also, the first and third controls noted significant improvements in stool consistency, measured as a decrease in the number of completely watery stools (<i>p</i> = 0.011 and <i>p</i> < 0.001, respectively). Conclusions: Nifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium–severe form of CDI. |
| format | Article |
| id | doaj-art-6b759ec8e47c4bb4a4e5bbd8e31925ec |
| institution | DOAJ |
| issn | 2079-6382 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj-art-6b759ec8e47c4bb4a4e5bbd8e31925ec2025-08-20T03:14:23ZengMDPI AGAntibiotics2079-63822025-04-0114440010.3390/antibiotics14040400Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile InfectionJasna Rahimić0Ervin Alibegović1Lana Lekić2Marijana Marković Boras3Amina Džidić-Krivić4Esma Karahmet Farhat5Emina Karahmet Sher6Faculty of Medicine, European University Kallos, Tuzla, XVIII Hrvatske Brigade 8, 75000 Tuzla, Bosnia and HerzegovinaDepartment of Clinical Center, Tuzla University, 75000 Tuzla, Bosnia and HerzegovinaFaculty of Health Studies, University of Sarajevo, Stjepana Tomića 1, 71000 Sarajevo, Bosnia and HerzegovinaInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UKInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UKFaculty of Food Technology, Juraj Strossmayer University of Osijek, 31000 Osijek, CroatiaInternational Society of Engineering Science and Technology UK, Nottingham NG7 1GN, UKBackground: All currently used therapeutic protocols and drugs for <i>Clostridioides difficile</i> infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a therapeutic protocol for a medium–severe form of CDI. In addition, the effects of a modified therapeutic protocol with standard monotherapy on the number of stools and stool consistency in a medium–severe CDI will be compared. Materials and Methods: A prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group of patients was treated with vancomycin monotherapy. The other group was treated with the modified therapeutic protocol (vancomycin + nifuroxazide). Results: The modified therapy with vancomycin + nifuroxazide demonstrated enhanced pharmacological efficacy in the management of CDI compared to the standard vancomycin monotherapy. Patients treated with dual therapy reported a significantly lower number of stools in first, second and third control; first control (4.47 ± 2.20 compared to 5.70 ± 1.91 in vancomycin group (<i>p</i> = 0.024)), second control (2.37 ± 0.85 compared to 3.13 ± 0.90 in vancomycin group (<i>p</i> = 0.001)), and third control (1.53 ± 0.51 compared to 1.80 ± 0.61 in vancomycin group (<i>p</i> = 0.035)). Also, the first and third controls noted significant improvements in stool consistency, measured as a decrease in the number of completely watery stools (<i>p</i> = 0.011 and <i>p</i> < 0.001, respectively). Conclusions: Nifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium–severe form of CDI.https://www.mdpi.com/2079-6382/14/4/400<i>Clostridioides difficile</i> infection (CDI)modified therapeutic protocolvancomycinnifuroxazide and dual antibiotic therapy |
| spellingShingle | Jasna Rahimić Ervin Alibegović Lana Lekić Marijana Marković Boras Amina Džidić-Krivić Esma Karahmet Farhat Emina Karahmet Sher Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection Antibiotics <i>Clostridioides difficile</i> infection (CDI) modified therapeutic protocol vancomycin nifuroxazide and dual antibiotic therapy |
| title | Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection |
| title_full | Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection |
| title_fullStr | Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection |
| title_full_unstemmed | Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection |
| title_short | Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection |
| title_sort | evaluating vancomycin monotherapy and dual therapy with nifuroxazide for medium severe clostridioides difficile infection |
| topic | <i>Clostridioides difficile</i> infection (CDI) modified therapeutic protocol vancomycin nifuroxazide and dual antibiotic therapy |
| url | https://www.mdpi.com/2079-6382/14/4/400 |
| work_keys_str_mv | AT jasnarahimic evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT ervinalibegovic evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT lanalekic evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT marijanamarkovicboras evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT aminadzidickrivic evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT esmakarahmetfarhat evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection AT eminakarahmetsher evaluatingvancomycinmonotherapyanddualtherapywithnifuroxazideformediumsevereclostridioidesdifficileinfection |